Spoke with @AlanKohler this week on @4DMedicalXV rapid US expansion, high-margin software model and European growth strategy. Encouraging to see increasing independent coverage of our growth trajectory. Full interview: intelligentinvestor.com.au/i…

_ @4DMedicalXV recently expanded into Europe via acquisition of contextflow, establishing a platform across ANZ, North America and Europe. The team attended ESTI 2026 in Salzburg, engaging thoracic imaging specialists and showcasing CT:VQ™.

_ @4DMedicalXV launches CLEAR, a clinical evidence program to fast-track CT:VQ™ into acute pulmonary embolism (PE), including a multi-centre prospective MGB-led study vs CTPA. Expands addressable US market to ~US$3bn across VQ and CTPA pathways | cdn-api.markitdigital.com/ap…

_ @4DMedicalXV expands into Europe via acquisition of contextflow, adding a European platform alongside ANZ and North America. The deal increases addressable market ~50% for ~6.5% cash and <0.5% dilution, strengthening its global lung health platform. cdn-api.markitdigital.com/ap…

At ATS2026 in Orlando, CT:VQ showed strong momentum, with LVRS success improving 46%→76% and record commercial interest across COPD and pulmonary disease. We also hosted a global webinar with leading clinicians discussing real-world impact.

_ @4DMedicalXV hosted a webinar on CT:VQ™ with Dr Joseph Mammarappallil (Duke), Matt Tucker and John Hester (Bell Potter). Discussion highlighted clinical adoption, ATS momentum and expanding LVRS use. ASX announcement: cdn-api.markitdigital.com/ap…

I joined David Koch at TIP Group’s Emerging Wealth Winners Conference in Sydney to discuss 4DMedical’s clinical and commercial opportunity. We covered CT adoption, its ~$500m US market potential, and why it could reshape lung imaging. Watch: youtu.be/PovWtMVwOKQ

This week we hosted the @AustSharesAsso at @4DMedicalXV's Melbourne headquarters. We showcased our core technology CT:VQ the way clinicians experience it - through real clinical workflows, with insights from Matt Tucker, James Odgers & Prof Tim O’Meara $4DX

Today 4DMedical shares three major milestones. 1. Commercial milestone: GSK Partnership 2. Regulatory milestone: UK Clearance for CT™ 3. Corporate milestone: S&P/ASX 200 Inclusion ASX announcement: cdn-api.markitdigital.com/ap…

I had the opportunity to speak with investors about what it really takes to turn capital into meaningful market impact at TIP Group's Emerging Wealth Winners Conference in Sydney this week. These are the moments where innovation moves from promise to scale.

4DMedical (ASX:4DX) has delivered a transformational period, with the stock rising more than 2000%, underpinned by rapid clinical adoption, regulatory milestones and strong institutional support. Ahead of presenting at @TIPGroup_Ltd Emerging Wealth Winners conference Founder, CEO and CTO, Dr Andreas Fouras speaks with The Stock Network’s @LelSmits about @4DMedicalXV's global expansion strategy and pathway to establishing CT:VQ™ as a new standard of care globally. 🌍 Transformational momentum and global validation 🇪🇺 Europe expansion and capital strategy 🫁 Commercial inflection and scaling economics Watch the full interview ⚡ youtu.be/Ko4Ex0IMWJY 🗓 Thursday, 16 April 2026 ⏰ 8AM - 6PM 📍 Royal Randwick Racecourse, Sydney Register now ⚡ eventbrite.com/e/tip-group-e… #4DX

This week I spoke at Impact Investment Summit APAC on the journey to disruption. It’s never a single breakthrough it’s building enduring companies with the right people, capital & ecosystem. AU now has the talent, research, and connectivity to turn innovation into global impact.

Spoke with Grady Wulff at Bell Potter on what’s driving 4DMedical: extracting more from standard lung scans no workflow change. Now in leading US hospitals. CT:VQ™ is the only FDA-approved, injection-free lung blood flow scan gaining traction. Watch: youtube.com/watch?v=srG8o76A…

Today we released our half-year report, a defining period for 4DMedical, showcasing execution, validation and growing global momentum. None of this is possible without the dedication of our incredible team. Half year report: announcements.asx.com.au/asx…

Australia is entering a once-in-a-generation moment for life sciences where solving real clinical problems isn’t just good science, it’s becoming one of the most powerful investment signals in the market. @4DMedicalXV

_ @4DMedicalXV's commercial momentum is accelerating. UMiami has commenced clinical use of CT:VQ™, becoming the second U.S. academic medical centre after Stanford. We also confirm a two-year agreement with Lahey Hospital & Medical Center | cdn-api.markitdigital.com/ap…

Coming to you live from the @RSNA conference, I've just held an investor webinar outlining the significant progress @4DMedicalXV is making. Commercial traction across major segments and RSNA confirms the shift happening now. I’m excited about where we are and where we’re going.

This week at RSNA, @4DMedicalXV showcased the FDA-cleared CT:VQ™ the world’s first non-contrast perfusion imaging technology. CT:VQ™ delivers ventilation perfusion from a standard chest CT with no contrast, no inhaled agents and no added scan time. rsna.org

4DMedical will be at RSNA this month, showcasing CT:VQ™ to the global radiology community. We’ll be meeting clinicians, partners and decision-makers, demonstrating how we help detect lung disease earlier and more precisely. Learn more: rsna.org @4DMedicalXV

This week in Sydney, we shared how 4DMedical is enabling earlier detection and treatment of lung disease improving outcomes for patients & clinicians. Thanks to those who joined us, including John Hester (Bell Potter) & our CCO, Matt Tucker. 4dmedical.com/investor/compa… @4DMedicalXV